Clinical Breast Cancer is an Elsevier specialty journal for clinical and translational breast cancer research, from detection and prevention to treatment. Breast oncologists, surgeons and translational researchers read it.
Clinical Breast Cancer is a peer-reviewed journal that publishes original articles on clinical and translational research in breast cancer, with eight issues a year. Its aims and scope statement says it is devoted to detection, diagnosis, prevention and treatment of breast cancer, with emphasis on recent scientific developments, and lists clinical research reports across therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumour genomics, biomarkers and chemoprevention strategies as areas of interest. The journal site includes an open access section for authors but does not state its overall access model in the text consulted, so no access model is recorded here. NLM records the title from 2000, first published in Dallas by the Cancer Information Group and since 2011 by Elsevier in New York, bimonthly from 2010 with supplements accompanying some volumes, and indexed in MEDLINE and PubMed.
Professor who runs the Centre Antoine Lacassagne, the regional cancer centre in Nice, as its Directeur Général.
Professor who is Medical Director of Trinity St James's Cancer Institute, Ireland's first academic comprehensive cancer institute, in Dublin.
Physician who is Medical Director of the Beaumont RCSI Cancer Centre, the OECI accredited cancer centre on the Beaumont Hospital campus in Dublin.
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
Shares Ductal carcinoma in situ (DCIS), PubMed & Europe PMC, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
Shares Ductal carcinoma in situ (DCIS), PubMed & Europe PMC, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
Shares Ductal carcinoma in situ (DCIS), Male breast cancer, PubMed & Europe PMC, HER2-positive breast cancer.
Shares Emmanuel Barranger, PubMed & Europe PMC.
Shares Male breast cancer, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.